{"url_path":"/sec/spro/8-k/2026-06-25/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Stockholders","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-25","source_url":"https://www.sec.gov/Archives/edgar/data/1701108/0001193125-26-283033-index.html","accession_number":"0001193125-26-283033","cik":"0001701108","ticker":"SPRO","issuer_name":"Spero Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1701108/0001193125-26-283033-index.html","primary_entity_key":"0001701108","primary_entity_name":"Spero Therapeutics, Inc."},"word_count":282,"has_tables":true,"body_markdown":"Item 5.07\n\nSubmission of Matters to a Vote of Stockholders\n\nOn June 23, 2026, the Company held its Annual Meeting. Of the 57,901,493 shares of common stock issued and outstanding and eligible to vote as of the record date of April 24, 2026, a quorum of 41,061,190 shares, or approximately 70.91% of the outstanding shares, were present in person or by proxy at the Annual Meeting.\n\nThe following actions were taken at the Annual Meeting:\n\n \n\n \n1.\n\nThe following nominees were reelected to serve on the Company’s board of directors as Class III directors until the Company’s 2029 annual meeting of stockholders, based on the following votes:\n\n \n\nName\n\n  \nVotes For\n \n  \nVotes Withheld\n \n  \nBroker Non-Votes\n \n\nMilind Deshpande, Ph.D.\n\n  \n \n26,745,670\n \n  \n \n2,254,740\n \n  \n \n12,060,780\n \n\nKathleen Tregoning\n\n  \n \n28,259,925\n \n  \n \n740,485\n \n  \n \n12,060,780\n \n\n \n\n \n2.\n\nThe selection of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified, based on the following votes:\n\n \n\nVotes For\n\n  \n\nVotes Against\n\n  \n\nVotes Abstained\n\n  \n\nBroker Non-Votes\n\n40,866,196\n  \n189,300\n  \n5,694\n  \nN/A\n\n \n\n \n3.\n\nThe advisory vote on the compensation of the Company’s named executive officers, as described in the Proxy Statement, was approved, based on the following votes:\n\n \n\nVotes For\n\n  \n\nVotes Against\n\n  \n\nVotes Abstained\n\n  \n\nBroker Non-Votes\n\n27,890,254\n  \n1,002,982\n  \n107,174\n  \n12,060,780\n\n \n\n \n4.\n\nThe amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the total number of shares of common stock authorized for issuance thereunder from 120,000,000 shares to 240,000,000 shares, was approved, based on the following votes:\n\n \n\nVotes For\n\n  \n\nVotes Against\n\n  \n\nVotes Abstained\n\n  \n\nBroker Non-Votes\n\n30,356,780\n  \n10,558,645\n  \n145,765\n  \nN/A\n\n \n\n \n5.\n\nThe Spero Therapeutics, Inc. 2026 Stock Incentive Plan, was approved, based on the following votes:\n\n \n\nVotes For\n\n  \n\nVotes Against\n\n  \n\nVotes Abstained\n\n  \n\nBroker Non-Votes\n\n25,379,610\n  \n3,567,416\n  \n53,384\n  \n12,060,780"}